ADC Summit 2015

SMi is delighted to announce that its 4th annual ADC Summit 2015 conference will take place on 18th - 19th May in London, UK.

Recent clinical successes have generated intense interest in antibody-drug conjugates and they are now an increasingly active area of biopharma research, with developers and manufacturers investing towards this revolutionary therapeutic. To develop ADCs that are more specific, more stable, and more effective; continued optimisation of the antibody, linker and payload of an ADC is critical.

This conference goes to the heart of the technological challenges and asks:
What does it take to develop superior ADCs and gain the clinical edge?

Join us as we share, confer and debate how to create the next wave of ADCs with better efficacy, lower toxicity and improved potency for clinical success.

REASONS TO ATTEND: ADC Summit 2015
Hear more about the payload developments
Receive updates on ADCs in clinical trials
Learn more about biodistribution and tumour penetrations
Aim for improvement of the therapeutic index
Discover strategies for effective targeting ADC off-target toxicities
Understand the status of the development of novel binding moieties

EXPERT SPEAKERS INCLUDE:

Mahendra Deonarain, Chief Scientific Officer, Antikor Biopharma Ltd.
David Thurston, Professor of Drug Discovery, King's College London
Angela Romanelli, Senior Director, Biomarkers, ImmunoGen, Inc.
Christophe Bonny, Chief Scientific Officer, Bicycle Therapeutics Limited
Klaus Bosslet, Head Discovery Oncology, Pharma Research & Early Development, Roche Innovation Center Penzberg
Iontcho Vlahov, Vice President of Discovery Chemistry, Endocyte, Inc.
Vijay Chudasama, Research Associate, University College London

Time: 8:30 am - 4:30 pm

URL:
Booking: http://atnd.it/19908-0

Price:
Conference and workshop: GBP 2098
Conference only: GBP 1499
Workshop only: GBP 599